logo

The Public Has Much More Trust in the FDA Than the Courts When It Comes to Abortion Access Decisions

As the fate of the abortion pill mifepristone remains in question, at least 7 in 10 U.S. adults say they’re concerned about unsafe abortions, increased maternal deaths
April 18, 2023 at 5:00 am UTC

For our latest data, news and analysis on public opinion around abortion,sign up for our daily health care newsletter.

As the Supreme Court weighs a decision on the Food and Drug Administration’s approval of the abortion pill mifepristone, more than half of Americans said they trust the agency to make decisions on abortion access in the United States, much more than the Supreme Court and federal judges, according to a new Morning Consultsurvey.

The Public Trusts the FDA Much More Than the Supreme Court and Federal Judges on Abortion Access Decisions

The share of U.S. adults who said they have “a lot” or “some” trust or “not much” or no trust “at all” in the following entities to make decisions about abortion access in the United States:
Morning Consult Logo
Survey conducted April 10-13, 2023, among a representative sample of 2,208 U.S. adults, with an unweighted margin of error of +/- 2 percentage points. Figures may not add up to 100% due to rounding.

Democrats trust the FDA while Republicans trust the Supreme Court to make abortion access decisions

  • Among all U.S. adults, 57% said they have “a lot” or “some” trust in the FDA to make abortion access decisions in the United States, compared with 43% who said the same for the Supreme Court and 40% for federal judges.
  • Democrats were more likely to say they trust the FDA (72%) than independents (48%) and Republicans (44%). Nearly 2 in 5 Democrats said they trust the Supreme Court and federal judges on abortion access decision-making. Meanwhile, 56% of Republicans said they trust the Supreme Court, and 47% said they trust federal judges.
  • Roughly a third of independents said they trusted either the Supreme Court or federal judges on abortion access decisions.

At Least 7 in 10 Americans Are Concerned About Unsafe Abortions, Increased Maternal Deaths Amid Abortion Pill Challenge

The share of U.S. adults who said they are concerned or not concerned about the following abortion and maternal health issues:
Morning Consult Logo
Survey conducted April 10-13, 2023, among a representative sample of 2,208 U.S. adults, with an unweighted margin of error of +/- 2 percentage points. Figures may not add up to 100% due to rounding.

Nearly 2 in 3 Americans are concerned about total or near-total abortion bans

  • As the legal battle over mifepristone continues to play out, more than 7 in 10 U.S. adults said they are concerned that people will turn to unsafe abortion methods and an increase in maternal health complications and deaths.
  • Nearly 2 in 3 adults said they are concerned that about half of the states in the country would implement total or near-total abortion bans, compared with about 1 in 5 who said they are not concerned and 1 in 8 who said they do not know or had no opinion. The issue has a stark partisan divide: 82% of Democrats said they were concerned about abortion bans, compared with 56% of independents and 45% of Republicans.
  • About 2 in 3 said they are concerned people would have to continue unwanted pregnancies. Meanwhile, over 3 in 5 said they are concerned that people will be unable to access abortion services in their area (63%), states would use the precedent of Roe v. Wade to overturn other rights like same-sex marriage (62%) and reproductive health and abortion providers in states where the procedure is legal would be overwhelmed (61%).

All eyes are on the Supreme Court

Close to one year after the Supreme Court overturned Roe v. Wade, it once again has a landmark abortion case to decide. The court could limit nationwide access to abortion pills — themost common method of abortionin the United States — after a ruling from a federal judge in Texas suspended the FDA’s 23-year-old approval of mifepristone.

Nearly half of the public (47%) said they oppose U.S. District Court Judge Matthew Kacsmaryk’s suspension of the drug’s approval, while about 3 in 10 said they support the ruling, according to a recent Morning Consultsurvey.

A federal appeals court overturned the suspension but left in place decisions to limit how the medication is distributed and how late into a pregnancy people can use it. Justice Samuel Alitosaid the courtwould decide on the next steps by midnight on Wednesday.

2023年4月10号至13号,,surveywas conducted among a representative sample of 2,208 U.S. adults, with an unweighted margin of error of plus or minus 2 percentage points.

国际扶轮的头像照片cky Zipp
Ricky Zipp
Health Care Analyst

瑞奇氧化锌碘仿糊是卫生保健产业分析师y Intelligence team, where he conducts research, authors analyst notes and advises leaders in the health care industry on how to apply insights to make better business decisions. Before joining Morning Consult, he worked as a health care journalist for Industry Dive and S&P Global Market Intelligence. Ricky graduated from Oregon State University with a bachelor’s degree in history and Northwestern University with a master’s degree in journalism.For speaking opportunities and booking requests, please email[email protected].

We want to hear from you.Reach out to this author or your Morning Consult team with any questions or comments. Contact Us